 |
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
ZIOPHARM Oncology to Present at the 11th Annual JMP Securities Research Conference
May 9, 2012
|
12.6 KB
|
| |
NEW YORK, May 9, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 11th Annual JMP Securities Research Conference on Tuesday, May 15, 2012 at 8:30 a.m. PT at The Ritz-Carlton in San Francisco, CA.
Dr. Lewis will provide an overview of the...
|
|
|
ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer
May 8, 2012
|
13.2 KB
|
| |
NEW YORK, May 8, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, today announced that it has appointed Jason A. Amello as Executive Vice President and Chief Financial Officer of the Company. In this position, Mr. Amello will lead...
|
|
|
ZIOPHARM Reports First Quarter Financial Results
May 3, 2012
|
18.4 KB
|
| |
NEW YORK, May 3, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today its financial results for the first quarter ended March 31, 2012, and provided an update on the Company's activities.
The Company's cash used in operations during the first quarter was $25.9 million, an increase of $17.7 million from $8.2 million for...
|
|
|
ZIOPHARM Oncology to Present at the Deutsche Bank Securities 37th Annual Health Care Conference
May 2, 2012
|
12.5 KB
|
| |
NEW YORK, May 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the Deutsche Bank Securities 37th Annual Health Care Conference on Wednesday, May 9, 2012 at 8:00 a.m. ET at The InterContinental Hotel in Boston.
Dr. Lewis will provide an ov...
|
|
|
ZIOPHARM Oncology to Present at the 19th Annual Future Leaders in the Biotech Industry Conference
Apr 16, 2012
|
12.5 KB
|
| |
NEW YORK, April 16, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 19th Annual Future Leaders in the Biotech Industry Conference on Friday, April 20, 2012 at 3:30 p.m. ET at The Millennium Broadway Hotel in New York City.
Dr. Lewis wil...
|
|
|
ZIOPHARM Oncology Presents Compelling Data Showing Palifosfamide Activity in Breast Cancer Models at AACR Meeting
Apr 3, 2012
|
16.9 KB
|
| |
CHICAGO, April 3, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today the presentation of two preclinical studies demonstrating compelling results for palifosfamide in breast cancer. The results were presented at the...
|
|
|
ZIOPHARM Oncology Presents Preclinical Data at AACR Meeting Demonstrating Significant Anti-Tumor Activity With Two Immunotherapies Expressed in Vivo by a Regulated Gene System
Apr 2, 2012
|
52.6 KB
|
| |
CHICAGO, April 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today the presentation of preclinical data demonstrating the significant anti-tumor activity of Interleukin-12 (IL-12) and interferon alpha (IFNα),...
|
|
|
ZIOPHARM Oncology Provides Update on PICASSO 3 Trial
Apr 2, 2012
|
14.0 KB
|
| |
Highly Rigorous Progression-Free Survival Trial Approaches 90% CompletionPFS Data Expected 2H 2012
NEW YORK, April 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, today announced an update on its PICASSO 3 trial, a random...
|
|
|
ZIOPHARM Oncology Announces Preclinical Data on Palifosfamide and IL-12 Gene Delivery to be Presented at the American Association for Cancer Research Annual Meeting 2012
Mar 27, 2012
|
50.4 KB
|
| |
NEW YORK, March 27, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new therapies for rare and difficult-to-treat cancers, announced today that data from four preclinical studies — three focused on metastatic breast cancer — will be prese...
|
|
|
ZIOPHARM Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 29, 2012
|
22.0 KB
|
| |
NEW YORK, Feb. 29, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today its financial results for the fourth quarter and full year ending December 31, 2011, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.Fourth Quarter Results
The Company's cash used in operations during th...
|
|
|
ZIOPHARM Oncology to Present at Upcoming Investor Conferences
Feb 21, 2012
|
13.1 KB
|
| |
NEW YORK, Feb. 21, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM, will present at the following investor conferences:2012 RBC Capital Markets' Global Healthcare ConferenceTuesday, February 28, 2012
New York Palace Hotel, New York, NY
11:00...
|
|
|
ZIOPHARM Oncology Reports Positive Preliminary Palifosfamide Overall Survival Data From Randomized Phase 2 Study in Soft Tissue Sarcoma
Feb 13, 2012
|
13.8 KB
|
| |
NEW YORK, Feb. 13, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today positive preliminary overall survival (OS) data from the Company's randomized, controlled Phase 2 trial of palifosfamide plus doxorubicin vs. dox...
|
|
|
ZIOPHARM Oncology to Present at the 14th Annual BIO CEO & Investor Conference
Feb 7, 2012
|
12.8 KB
|
| |
NEW YORK, Feb. 7, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 9:30 a.m. Eastern Time at The Waldorf=Astoria in New York City.
Dr. Lewis will provide an overv...
|
|
|
ZIOPHARM Announces FDA Acceptance of IND for Oral Palifosfamide
Feb 6, 2012
|
13.1 KB
|
| |
NEW YORK, Feb. 6, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for the oral dosing of palifosfamide ...
|
|
|
ZIOPHARM Oncology Announces Recommendation by Independent Data Monitoring Committee to Continue Phase 3 Study of Palifosfamide in Metastatic Soft Tissue Sarcoma
Jan 30, 2012
|
12.8 KB
|
| |
NEW YORK, Jan. 30, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today that the Independent Data Monitoring Committee (IDMC) has unanimously recommended continuation of the international, randomized, double-blinded, ...
|
|
|
ZIOPHARM Oncology Prices Public Offering of Common Stock
Jan 20, 2012
|
12.6 KB
|
| |
NEW YORK, Jan. 20, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 9,650,000 shares of its common stock at a public offering price of $5.20 per share. All of the shares are being sold by ZIOPHARM. The offering is expected to close on January 25, 2012, subject to custom...
|
|
|
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock
Jan 19, 2012
|
13.1 KB
|
| |
NEW YORK, Jan. 19, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP - News) today announced that it intends to commence an underwritten public offering of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM.
J.P. Morgan Securities LLC will act as book-running manager for the prop...
|
|
|
ZIOPHARM Oncology to Present at the 30th Annual J.P. Morgan Healthcare Conference
Dec 21, 2011
|
13.6 KB
|
| |
NEW YORK--(BUSINESS WIRE)--
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan
Lewis, M.D., Ph.D., Chief Executive Officer, will present at the
upcoming 30th Annual J.P. Morgan Healthcare Conference on
Wednesday, January 11, 2012, at 2:30 pm Pacific Time, at the Westin St.
Francis Hotel...
|
|
|
ZIOPHARM Oncology to Present at the Oppenheimer 22nd Annual Healthcare Conference
Dec 8, 2011
|
13.4 KB
|
| |
NEW YORK--(BUSINESS WIRE)--
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan
Lewis, M.D., Ph.D., Chief Executive Officer, will present at the
Oppenheimer 22nd Annual Healthcare Conference on Wednesday,
December 14, 2011, at 1:50 pm Eastern Time, at The Waldorf-Astoria in
New York City...
|
|
|
ZIOPHARM Granted European Patent Allowance for Palifosfamide
Dec 7, 2011
|
14.2 KB
|
| |
--Additional Patent Issuance for Darinaparsin--
NEW YORK--(BUSINESS WIRE)--
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it has
received an allowance from the European Patent Office for Patent
Application No. 05 821 125.1, entitled "Salts of Isophosphoramide
mustard a...
|
|
|
| |
Recent Releases
May 9, 2012
ZIOPHARM Oncology to Present at the 11th Annual JMP Securities Research Conference
May 8, 2012
ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer
May 3, 2012
ZIOPHARM Reports First Quarter Financial Results
more »
|
